227 results on '"Tan, D.S.W."'
Search Results
2. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
4. P2.09-01 A Large Asian Real-World EGFR exon 20Insertion Mutated NSCLC Dataset with Deep Genomic Characterization
5. EP12.01-31 Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer
6. MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
7. P2.09-17 OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer
8. P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study
9. EP04.05-05 Singapore Lung Cancer Screening through Integrating CT with Other Biomarkers (SOLSTICE), A Single Arm Lung Cancer Screening Study
10. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
11. 15MO Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib
12. BLU-945 Monotherapy and Combination With Osimertinib in Previously Treated Patients With Advanced EGFR-Mutant (EGFRm) NSCLC in Phase 1/2 SYMPHONY Study
13. 227MO Characterization of minimal residual disease (MRD) post-radiotherapy (RT) in nasopharyngeal carcinoma (NPC) patients identifies a favorable subgroup with low risk of relapse
14. 362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial
15. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
16. Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study
17. 126P Clonal architecture and genomic features of smoking versus non-smoking oncogene-driven East-Asian non-small cell lung cancer
18. 463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
19. P2.13-02 Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)
20. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
21. EP08.02-148 Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
22. EP08.02-045 Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer
23. 1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
24. 980P Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
25. 986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study
26. EP16.03-036 Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
27. Trials without borders—decentralized trials and ensuring access to novel cancer therapies during a global pandemic
28. 26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1
29. 61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
30. 142P Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
31. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
32. 534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
33. 1221P Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
34. Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future
35. 1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
36. 2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
37. 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
38. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
39. 1224P Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
40. 911P Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
41. 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
42. Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”
43. 162P Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
44. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
45. MO01.35 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
46. 192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations
47. 299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC
48. 266O Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939
49. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
50. 1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.